Profiles of patients with psoriasis for appointment gene-engineering biological therapy — clinical justification

Abstract

Psoriasis is a chronic immune-mediated disease with predominant damage to the skin and musculoskeletal system.
 This paper describes the clinical manifestations of psoriasis requiring a special therapeutic approach. The profiles of patients who showed the early assignment of genetic engineering biological therapy: patients with moderate and severe psoriasis, with rashes of problem localization (skin of the face, scalp, genital area and palmar-plantar region), with severe psoriatic lesion of the nail plates, as well as psoriatic arthritis.
 Clinical cases of rapid and pronounced resolution of rashes with the use of the new drug netakimab (Efleira) in a dosage of 120 mg according to the standard regimen psoriasis patients with indications for systemic or phototherapy.